The immune microenvironment of uterine adenosarcomas.
Adenosarcoma
CD3+
CD8+
Immune infiltrate
Immunotherapy
Microenvironment
Journal
Clinical sarcoma research
ISSN: 2045-3329
Titre abrégé: Clin Sarcoma Res
Pays: England
ID NLM: 101577890
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
09
2019
accepted:
27
01
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
2
4
2020
Statut:
epublish
Résumé
Uterine adenosarcoma (UA) is an extremely rare sarcoma subtype. There has been limited evaluation of the immune microenvironment in these tumors. The objective of this study is to examine and describe the immune infiltrate and PD-1/PD-L1 expression in UA and to correlate these changes in the tumor micro-environment with the overall survival status or the disease-free survival status (DFSS), respectively. Patients (pts) treated at our center from 1982 to 2014 with UA were identified. Fifteen cases had tumor paraffin-embedded blocks available. Immunohistochemistry studies for CD3, CD8, FOXP3, CD163, PD-1 and PD-L1 (clone 22C3) were performed. Image analysis was used to assess the density (cells/mm Immune infiltrate analysis median (range) density in cells/mm In conclusion, this is the first report characterizing the presence of immune infiltrate and PD-1/PD-L1 expression in UA. CD3+ CD8+ T-cells density may be prognostic. The immune-responsiveness of UA needs to be further investigated in a larger study.
Sections du résumé
BACKGROUND
BACKGROUND
Uterine adenosarcoma (UA) is an extremely rare sarcoma subtype. There has been limited evaluation of the immune microenvironment in these tumors. The objective of this study is to examine and describe the immune infiltrate and PD-1/PD-L1 expression in UA and to correlate these changes in the tumor micro-environment with the overall survival status or the disease-free survival status (DFSS), respectively.
METHODS
METHODS
Patients (pts) treated at our center from 1982 to 2014 with UA were identified. Fifteen cases had tumor paraffin-embedded blocks available. Immunohistochemistry studies for CD3, CD8, FOXP3, CD163, PD-1 and PD-L1 (clone 22C3) were performed. Image analysis was used to assess the density (cells/mm
RESULTS
RESULTS
Immune infiltrate analysis median (range) density in cells/mm
CONCLUSIONS
CONCLUSIONS
In conclusion, this is the first report characterizing the presence of immune infiltrate and PD-1/PD-L1 expression in UA. CD3+ CD8+ T-cells density may be prognostic. The immune-responsiveness of UA needs to be further investigated in a larger study.
Identifiants
pubmed: 32231779
doi: 10.1186/s13569-020-0127-0
pii: 127
pmc: PMC7103067
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Consent for publicationThere are no conflicts of interests to report. All authors consented to publication.Competing interestsThe authors declare that they have no competing interests.
Références
Gynecol Oncol. 2010 Nov;119(2):305-8
pubmed: 20688363
Gynecol Oncol. 2009 Jul;114(1):105-10
pubmed: 19411095
J Pathol. 2009 Jun;218(2):222-31
pubmed: 19274709
Hum Pathol. 2015 Mar;46(3):357-65
pubmed: 25540867
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Expert Rev Anticancer Ther. 2018 Nov;18(11):1093-1100
pubmed: 30169984
Cancer Sci. 2006 Dec;97(12):1374-80
pubmed: 16995877
Oncoimmunology. 2017 Oct 26;7(2):e1386828
pubmed: 29308311
Hum Pathol. 1990 Apr;21(4):363-81
pubmed: 2156771
Immunity. 2017 Feb 21;46(2):197-204
pubmed: 28228279
Gynecol Oncol. 2010 Jan;116(1):131-9
pubmed: 19853898
PLoS One. 2013 Dec 11;8(12):e82870
pubmed: 24349382
Cancer Immunol Res. 2014 Jul;2(7):690-698
pubmed: 24866169
Int J Gynecol Cancer. 2018 Sep;28(7):1297-1310
pubmed: 30044322
Curr Treat Options Oncol. 2017 Aug 24;18(10):59
pubmed: 28840453
Cancer. 2017 Sep 1;123(17):3291-3304
pubmed: 28463396
Cancer. 2017 Sep 1;123(17):3285-3290
pubmed: 28440953
J Immunother Cancer. 2017 Dec 19;5(1):100
pubmed: 29254498
Gynecol Oncol. 2016 Oct;143(1):120-127
pubmed: 27470997
J Surg Oncol. 2011 Apr;103(5):380-5
pubmed: 21400519
Cancer Immunol Immunother. 2014 Jun;63(6):545-57
pubmed: 24658839
Gynecol Oncol. 2017 Mar;144(3):524-530
pubmed: 28109626
Curr Oncol Rep. 2016 Nov;18(11):68
pubmed: 27718181
Oncologist. 2018 Jan;23(1):71-83
pubmed: 28935774
Gynecol Oncol Res Pract. 2015 Dec 02;2:11
pubmed: 27231571